Thermo Fisher (TMO) Q2 2026: Guidance Raised, Cash Down 59% YTD After $9.1B Clario

Half of Thermo Fisher's reported revenue growth was bought rather than earned. The company's own non-GAAP reconciliation in the 10-Q splits the second quarter's 10% reported growth into 5 points of organic gain, 5 points from acquisitions and 1 point from currency (components round independently, so they do not sum exactly). That matters because the purchase was expensive: cash fell from $9,852 million at year end to $4,064 million at June 27, and goodwill now stands at 104% of the company's entire book equity, up from 92% at year end. Management nonetheless raised full-year guidance on the July 23 earnings call — revenue to $47.4–48.1 billion and adjusted EPS to $24.93–25.33. The underlying business did improve — organic growth accelerated to 5% in the quarter from 3% across the first half — but investors are now funding that recovery through a far more leveraged balance sheet.

One framing point the headline numbers obscure: Clario Holdings closed on March 24, 2026, four days before the first quarter ended (Note 2). The cash and goodwill damage was therefore booked largely in Q1; Q2 is the first full quarter of Clario revenue and amortization. Every balance-sheet and cash-flow comparison below is a six-month movement, not a three-month one.

1. Balance Sheet

1-1. Major asset movements

Comparisons run from December 31, 2025 (fiscal year end) to June 27, 2026, the standard basis for a 10-Q. All figures are from the condensed consolidated balance sheet.